Back to top

Is Anthem (ANTM) Stock Outpacing Its Medical Peers This Year?

Read MoreHide Full Article

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Anthem (ANTM - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.

Anthem is a member of our Medical group, which includes 756 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.

The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. ANTM is currently sporting a Zacks Rank of #2 (Buy).

The Zacks Consensus Estimate for ANTM's full-year earnings has moved 0.62% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.

Based on the most recent data, ANTM has returned 19.75% so far this year. Meanwhile, stocks in the Medical group have gained about 11.06% on average. As we can see, Anthem is performing better than its sector in the calendar year.

Looking more specifically, ANTM belongs to the Medical - HMOs industry, a group that includes 13 individual stocks and currently sits at #39 in the Zacks Industry Rank. This group has gained an average of 21.52% so far this year, so ANTM is slightly underperforming its industry in this area.

Investors with an interest in Medical stocks should continue to track ANTM. The stock will be looking to continue its solid performance.




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Anthem, Inc. (ANTM) - free report >>

More from Zacks Tale of the Tape

You May Like